Aclaris Therapeutics, Inc. expanded its senior R&D team and recently appointed Ian Anderson, Ph.D., as Executive Vice President, Translational Research & Development. Dr. Anderson brings more than 30 years of immunology research experience in drug development, from discovery through Phase 2. He previously held senior scientific leadership roles at Flame Biosciences, Janssen Pharmaceutical, MedImmune and Cambridge Antibody Technology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.22 USD | -8.96% | -3.17% | +16.19% |
May. 07 | Transcript : Aclaris Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.19% | 95.49M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- ACRS Stock
- News Aclaris Therapeutics, Inc.
- Aclaris Therapeutics, Inc. Appoints Ian Anderson as Executive Vice President, Translational Research & Development